Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Calian Group (CGY) has announced the acquisition of two Ottawa-based health care companies
  • Both Allphase Clinical Research and Alio Health Services operate within the medical software industry
  • Total consideration is valued at C$14.5 million, comprised of C$12 million cash and 62,054 common shares
  • The acquisitions come as Calian looks to strengthen its health segment and reach new services and customers
  • Calian shares are up 1.07 per cent to C$42.70, with a market cap of C$342.11 million

Calian Group (CGY) has announced the acquisition of Allphase Clinical Research Services and Alio Health Services.

The acquisition of the Ottawa-based companies is a move by Calian to strengthen its health segment and gain access to new services and customer divisions.

Allphase Clinical Research is a contract research organisation that offers clinical development management and strategy services for pharmaceutical and medical device companies.

Alio, on the other hand, specializes in the design and implementation of Patient Support Programs.

Its proprietary HOME™ software is designed to streamline the scheduling and delivery of health services for a range of health care institutions and home-care providers.

“This acquisition will accelerate our access to emerging technologies and business in new markets, encompassing hospitals, patient support at home and clinical trial services,” said Gordon McDonald, Vice President of Health at Calian Group. 

“As we leverage the HOME™ software application across Calian’s existing health services portfolio, we see significant potential to drive new business and create efficiencies within our current health services.” 

The total consideration for the acquisition is valued at C$14.5 million, which is comprised of C$12 million cash and 62,054 common shares.

“This strategic acquisition supports all four pillars of our growth framework. It diversifies our customer base into pharmaceuticals, home care and hospitals, and supports Calian’s innovation agenda with services enabled by sophisticated software,” said Kevin Ford, CEO of Calian Group. 

“We see opportunities to evolve this software within our Health segment and strengthen Calian’s position in technology-enabled health solutions.”

Calian shares are up 1.07 per cent to C$42.70, with a market cap of C$342.11 million.

More From The Market Herald

" Diagnos (TSXV:ADK) closes non-brokered private placement

Diagnos (ADK) has closed its non-brokered private placement for gross proceeds of $500,000.
NurExone Exosomes

" NurExone (TSXV:NRX) reports Q3 2022 financial results & provides corporate update

NurExone Biologic (NRX) reported its financial results for the quarter ended September 30, 2022.

" Wellteq (CSE:WTEQ) announces shareholder approval for plan of arrangement with AHI

Wellteq Digital Health (WTEQ) has announced that holders of its common shares have approved its plan of arrangement.

" Empower Clinics (CSE:EPW) names new General Manager of Medisure Labs

Empower Clinics (EPW) has appointed Eric Christian as the new General Manager of its medical diagnostics laboratory business, Medisure Labs.